ECI’s Integrated and Continuous Biomanufacturing Conference (ICB) is the world’s premiere conference in the area of continuous biomanufacturing. It accepts only the highest-quality scientific papers. No commercial entities influence the scientific programming. Integrated and continuous biomanufacturing is being implemented across the biopharmaceutical industry. It is a powerful process intensification tool enabling cost-effective, lean, and agile manufacturing facilities. The development of these technologies has been discussed in our past conferences ICB I (2013), ICB II (2015), and ICB III (2017). ICB IV (2019) will showcase the implementation of these technologies for GMP biomanufacturing using case studies of clinical and/or commercial bioprocesses. Other topics will include: Methodologies for ICB process development Automation, control and digitalization strategies for ICB New examples of integration between vial thaw and drug product Validation of continuous viral inactivation and viral clearance Continuous biomanufacturing beyond CHO and/or proteins ICB IV will bring together leading scientists and engineers from academia, industry, and regulatory agencies who are actively engaged in the field of integrated continuous biomanufacturing. We look forward to welcoming you to Brewster (Cape Cod), Massachusetts, USA in October 2019 for a scientific exchange in pursuit of advancing the adoption of ICB and serving patients’ needs.